7 results on '"Moore, Jonathan L."'
Search Results
2. Metabolic tumour and nodal response to neoadjuvant chemotherapy on FDG PET-CT as a predictor of pathological response and survival in patients with oesophageal adenocarcinoma.
- Author
-
Moore, Jonathan L., Subesinghe, Manil, Santaolalla, Aida, Green, Michael, Deere, Harriet, Van Hemelrijck, Mieke, Lagergren, Jesper, Chicklore, Sugama, Maisey, Nick, Gossage, James A., Kelly, Mark, Baker, Cara R., Davies, Andrew R., Jacques, A., Griffin, N., Goh, V., Ngan, S., Owczarczyk, K., Sita-Lumsden, A., and Qureshi, A.
- Subjects
- *
POSITRON emission tomography computed tomography , *NEOADJUVANT chemotherapy , *OVERALL survival , *GASTRIC bypass , *RECEIVER operating characteristic curves , *ESOPHAGEAL cancer - Abstract
Objectives : 2-deoxy-2[18F]Fluoro-d-glucose (FDG) PET-CT has an emerging role in assessing response to neoadjuvant therapy in oesophageal cancer. This study evaluated FDG PET-CT in predicting pathological tumour response (pTR), pathological nodal response (pNR) and survival. Methods: Cohort study of 75 patients with oesophageal or oesophago-gastric junction (GOJ) adenocarcinoma treated with neoadjuvant chemotherapy then surgery at Guy's and St Thomas' NHS Foundation Trust, London (2017–2020). Standardised uptake value (SUV) metrics on pre- and post-treatment FDG PET-CT in the primary tumour (mTR) and loco-regional lymph nodes (mNR) were derived. Optimum SUVmax thresholds for predicting pathological response were identified using receiver operating characteristic analysis. Predictive accuracy was compared to PERCIST (30% SUVmax reduction) and MUNICON (35%) criteria. Survival was assessed using Cox regression. Results: Optimum tumour SUVmax decrease for predicting pTR was 51.2%. A 50% cut-off predicted pTR with 73.5% sensitivity, 69.2% specificity and greater accuracy than PERCIST or MUNICON (area under the curve [AUC] 0.714, PERCIST 0.631, MUNICON 0.659). Using a 30% SUVmax threshold, mNR predicted pNR with high sensitivity but low specificity (AUC 0.749, sensitivity 92.6%, specificity 57.1%, p = 0.010). pTR, mTR, pNR and mNR were independent predictive factors for survival (pTR hazard ratio [HR] 0.10 95% confidence interval [CI] 0.03–0.34; mTR HR 0.17 95% CI 0.06–0.48; pNR HR 0.17 95% CI 0.06–0.54; mNR HR 0.13 95% CI 0.02–0.66). Conclusions: Metabolic tumour and nodal response predicted pTR and pNR, respectively, in patients with oesophageal or GOJ adenocarcinoma. However, currently utilised response criteria may not be optimal. pTR, mTR, pNR and mNR were independent predictors of survival. Key Points: • FDG PET-CT has an emerging role in evaluating response to neoadjuvant therapy in patients with oesophageal cancer. • Prospective cohort study demonstrated that metabolic response in the primary tumour and lymph nodes was predictive of pathological response in a cohort of patients with adenocarcinoma of the oesophagus or oesophago-gastric junction treated with neoadjuvant chemotherapy followed by surgical resection. • Patients who demonstrated a response to neoadjuvant chemotherapy in the primary tumour or lymph nodes on FDG PET-CT demonstrated better survival and reduced rates of tumour recurrence. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
3. Effect of peri-operative chemotherapy regimen on survival in the treatment of locally advanced oesophago-gastric adenocarcinoma – A comparison of the FLOT and 'MAGIC' regimens.
- Author
-
Moore, Jonathan L., Kumar, Sacheen, Santaolalla, Aida, Patel, Pranav H., Kapiris, Matthaios, Van Hemelrijck, Mieke, Maisey, Nick, Hill, Mark, Lagergren, Jesper, Gossage, James A., Kelly, Mark, Chaudry, Asif, Allum, William H., Baker, Cara R., Cunningham, David, and Davies, Andrew R.
- Subjects
- *
STOMACH tumors , *ADENOCARCINOMA , *ADJUVANT chemotherapy , *DRUG efficacy , *PERIOPERATIVE care , *FOLINIC acid , *CONFIDENCE intervals , *ANTINEOPLASTIC agents , *SURGICAL complications , *CANCER patients , *ANTIMETABOLITES , *FLUOROURACIL , *COMPARATIVE studies , *EPIRUBICIN , *CISPLATIN , *DOCETAXEL , *SURVIVAL analysis (Biometry) , *DESCRIPTIVE statistics , *DRUGS , *OXALIPLATIN , *PROGRESSION-free survival , *PATIENT compliance , *ESOPHAGEAL tumors , *LONGITUDINAL method , *PROPORTIONAL hazards models , *EVALUATION - Abstract
Peri-operative chemotherapy improves survival in patients with locally advanced oesophago-gastric adenocarcinoma. Two regimens with proven survival benefits are epirubicin, cisplatin plus capecitabine or fluorouracil (Medical Research Council Adjuvant Gastric Infusional Chemotherapy, MAGIC) and fluorouracil plus leucovorin, oxaliplatin, and docetaxel (FLOT). This study aimed to compare the effect of these regimens on survival (primary aim) and pathological response, surgical complications, adverse events and chemotherapy completion rates. Cohort study including 946 patients treated with FLOT (n = 257) or MAGIC (n = 689) who underwent surgical resection for oesophageal (n = 743) or gastric (n = 203) adenocarcinoma between 2002 and 2021 at St Thomas' Hospital or The Royal Marsden Hospital, London, UK. Survival analysis was performed using multivariable Cox regression, providing hazard ratios (HRs) with 95% confidence intervals (CIs) adjusted for age, sex, clinical T-stage, clinical N-stage, tumour grade and presence of signet ring cells. Patients treated with FLOT had better overall survival (HR = 0.69, 95% CI 0.50–0.94) and disease-free survival (HR = 0.75, 95% CI 0.58–0.98) than MAGIC. Patients treated with FLOT were more likely to have a complete pathological response (9.5% FLOT versus 5.5% MAGIC, p = 0.027) and were less likely to have a positive resection margin (19.1% FLOT versus 32.2% MAGIC, p < 0.001). The stratified analysis revealed similar results for oesophageal and gastric tumours. Rates of surgical complications, chemotherapy-associated adverse events and completion were similarly distributed between treatment groups. Patients with oesophageal or gastric adenocarcinoma treated with peri-operative FLOT had better survival and pathological response than those treated with peri-operative MAGIC. Rates of surgical complications, adverse events and chemotherapy completion were comparable. • Better survival in patients treated with fluorouracil plus leucovorin, oxaliplatin and docetaxel. • Better pathological and radiological response to chemotherapy with FLOT. • Higher rates of complete pathological response in patients treated with FLOT. • Patients treated with FLOT were less likely to have a positive resection margin. • Comparable rates of surgical complications, adverse events and chemo completion. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
4. Particularizing Patent Pleading: Pleading Patent Infringement in a Post-Twombly World.
- Author
-
Moore, Jonathan L.
- Subjects
- *
ACTIONS & defenses (Law) , *PATENT infringement , *PATENT suits , *CIVIL procedure , *PLEADING - Abstract
The article explores the impact of the changes related to pleading in civil litigation on the pleading requirements for patent infringement litigation in the U.S. The author observes that changing pleading standards will present a mechanism for curbing litigation abuse. Additionally, he believes that particularized patent pleading offers an efficient method for alleged infringers to contest nuisance-value claims.
- Published
- 2010
5. TIME FOR AN UPGRADE: AMENDING THE FEDERAL RULES OF EVIDENCE TO ADDRESS THE CHALLENGES OF ELECTRONICALLY STORED INFORMATION IN CIVIL LITIGATION.
- Author
-
Moore, Jonathan L.
- Subjects
- *
FEDERAL regulation , *ELECTRONIC evidence , *ACTIONS & defenses (Law) , *ELECTRONIC information resources -- Law & legislation , *TRIALS (Law) , *DOCUMENTARY evidence - Abstract
In recent years, electronically stored information (ESI) has begun to play an increasingly important role in civil litigation. Although the e-discovery amendments to the Federal Rules of Civil Procedure in 2006 provided guidelines for the discovery of this information, no accompanying changes were made to the Federal Rules of Evidence to govern the admissibility of this information at trial. This article outlines the vastly different ways courts have addressed this problem in three areas: authentication, hearsay, and the best evidence rule. After discussing the various approaches courts take in these areas, this article proposes specific amendments to the Federal Rules of Evidence that would provide guidance to courts and litigants as to the admissibility of electronically stored information at trial. [ABSTRACT FROM AUTHOR]
- Published
- 2010
6. AN OVERVIEW OF THE NEW.
- Author
-
Rhoads, Mark B. and Moore, Jonathan L.
- Subjects
- *
STEM education , *FOREIGN students , *INDUSTRIAL relations , *EMPLOYER attitudes - Published
- 2016
7. Patient perspectives on key symptoms and preferences for follow-up after upper gastro-intestinal cancer surgery.
- Author
-
Pucher, Philip H., Coombes, Annie, Evans, Orla, Taylor, Joanna, Moore, Jonathan L., White, Annabelle, Lagergren, Jesper, Baker, Cara, Kelly, Mark, Gossage, James A., Dunn, Jason, Zeki, Sebastian, Byrne, Ben E., Andreyev, Jervoise, Davies, Andrew R., and RESTORE study group, Guy’s, St Thomas’ Oesophago-gastric research group
- Abstract
Purpose: Long-lasting symptoms and reductions in quality of life are common after oesophago-gastric surgery. Post-operative follow-up has traditionally focussed on tumour recurrence and survival, but there is a growing need to also identify and treat functional sequelae to improve patients' recovery.Methods: An electronic survey was circulated via a British national charity for patients undergoing oesophago-gastric surgery and their families. Patients were asked about post-operative symptoms they deemed important to their quality of life, as well as satisfaction and preferences for post-operative follow-up. Differences between satisfied and dissatisfied patients with reference to follow-up were assessed.Results: Among 362 respondents with a median follow-up of 58 months since surgery (range 3-412), 36 different symptoms were reported as being important to recovery and quality of life after surgery, with a median of 13 symptoms per patient. Most (84%) respondents indicated satisfaction with follow-up. Satisfied patients were more likely to have received longer follow-up (5-year or longer follow-up 60% among satisfied patients vs 27% among unsatisfied, p < 0.001). These were also less likely to have seen a dietitian as part of routine follow-up (37% vs 58%, p = 0.005).Conclusion: This patient survey highlights preferences regarding follow-up after oesophago-gastrectomy. Longer follow-up and dietician involvement improved patient satisfaction. Patients reported being concerned by a large number of gastrointestinal and non-gastrointestinal symptoms, highlighting the need for multidisciplinary input and a consensus on how to manage the poly-symptomatic patient. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.